About AlgoTx
AlgoTx is a company based in Suresnes (France) founded in 2018 by Stephane Thiroloix and Olivier Bohuon. It operates as a HealthTech. AlgoTx has raised $39.29 million across 4 funding rounds from investors including Bpifrance, Relyens and Omnes Capital. AlgoTx offers products and services including ATX01. AlgoTx operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Suresnes, France
- Founders Stephane Thiroloix, Olivier Bohuon
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$39.29 M (USD)
in 4 rounds
-
Latest Funding Round
$21.42 M (USD), Series B
Mar 14, 2023
-
Investors
Bpifrance
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AlgoTx
AlgoTx offers a comprehensive portfolio of products and services, including ATX01.
ATX01 is developed for complex pain relief treatment.
People of AlgoTx
Unlock access to complete
Unlock access to complete
Funding Insights of AlgoTx
AlgoTx has successfully raised a total of $39.29M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $21.42 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AlgoTx
AlgoTx has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Relyens and Omnes Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on energy transition and sustainable investments across Europe.
|
Locked | Locked | Locked | |
|
UI Investissement is engaged in private equity and investment services.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for AlgoTx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AlgoTx
Investment portfolio details for AlgoTx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AlgoTx
Detailed financials for AlgoTx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Algotx Comparisons
Peer comparison for AlgoTx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AlgoTx
AlgoTx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Pain treatment products are developed through reformulation technologies.
|
Detailed competitors of AlgoTx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Algotx
Complete news archive for AlgoTx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AlgoTx
AlgoTx was founded in 2018.
AlgoTx is headquartered in Suresnes, France. It is registered at Suresnes, Ile-de-france, France.
Stephane Thiroloix is the current CEO of AlgoTx. They have also founded this company.
AlgoTx is a funded company, having raised a total of $39.29M across 4 funding rounds to date.
AlgoTx is engaged in the development of novel non-opioid solutions for complex pain relief. The company prioritizes indications lacking proven therapies, such as Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Erythromelalgia. Its lead program, ATX01, is in Phase 2 clinical development, targeting specific patient needs through topical administration to minimize systemic side effects. Operations are based in France, with research and clinical trials conducted in the US and Europe.
AlgoTx's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
AlgoTx offers ATX01.
AlgoTx has 4 investors. Key investors include Bpifrance, Relyens, Omnes Capital, and UI Investissement.